Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24407547 | 0.86 | MAP2K1 (0.58) | MAP2K1MAP2K2 | |
| SCHEMBL31096232 | 0.86 | MAP2K1 (0.58) | MAP2K1MAP2K2 | |
| SCHEMBL24407575 | 0.83 | FLT1 (0.43) | MAP2K1MAP2K2KDRFLT1SYK | |
| SCHEMBL24407530 | 0.82 | FLT1 (0.42) | MAP2K1MAP2K2KDRFLT1SYK | |
| SCHEMBL26047568 | 0.82 | MAP2K1 (0.46) | MAP2K1MAP2K2KDRFLT1P2RX7 | |
| SCHEMBL26048508 | 0.81 | MAP2K1 (0.41) | MAP2K1MAP2K2KDRFLT1SYK | |
| SCHEMBL24407577 | 0.81 | MAP2K1 (0.46) | MAP2K1MAP2K2KDRFLT1P2RX7 | |
| SCHEMBL24407548 | 0.81 | MAP2K1 (0.40) | MAP2K1MAP2K2KDRFLT1P2RX7 | |
| SCHEMBL24407522 | 0.80 | MAP2K1 (0.60) | MAP2K1MAP2K2 | |
| SCHEMBL24407573 | 0.80 | MAP2K1 (0.60) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4233834-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233865-A2 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFlection Therapeutics, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | NFLECTION THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220144819-A1 | NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | NFLECTION THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013227-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKS | HTR3C, NDUFA13, NDUFAF3 | MAP2K1 4087/4885MAP2K2 3533/4885KDR 2185/4885 |
| US-20220144819-A1 | NAPHTHYRIDINONE-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS | TYR, POLR1C, NQO1 | MAP2K1 461/4885MAP2K2 348/4885KDR 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.